AMPK Signaling Activator XIII; ZLN005

Code: 5043770001 D2-231

Biochem/physiol Actions

Secondary Targetluciferase activity inhibitor

Primary Targetincreases cellular ADP/ATP ratio via mitochondria respiration uncoupling

Cell ...


read more

Your Price
€324.65 EACH
Discontinued
€399.32 inc. VAT

Biochem/physiol Actions

Secondary Targetluciferase activity inhibitor

Primary Targetincreases cellular ADP/ATP ratio via mitochondria respiration uncoupling

Cell permeable: yes

General description

A cell-permeable benzimidazole that, in addition to its inhibitory potency against luciferase activity (IC50﹤10 nM), is reported to activate AMPK signaling by increasing cellular ADP/ATP ratio via mitochondria respiration uncoupling in a cell type-specific manner, effectively activating AMPK & PGC-1α in muscle, but not liver, cell types both in cultures (5-20 µM & 1-24 h in rat L6 myotubes; no effect in primary rat hepatocytes) in vitro and in db/db mice (gastrocnemius/calf muscle, but not liver tissue; 15 mg/kg/day via p.o. for 6 wks) in vivo. ZLN005 is orally available in mice (plasma Cmax & Tmax = 3.7 µM & 15 min, respectively, following single 15 mg/kg oral dosage to db/db mice) and is efficacious in improving glucose (1.5 g/kg i.p.) tolerance among 4-wk-treated and insulin (1 unit/kg) tolerance among 5-wk treated db/db mice (by 14% and 18%, respectively; 15 mg/kg/day via p.o.) in vivo without any apparent effects on body weight or food intake among db/db or non-diabetic controls.

A cell-permeable benzimidazole that, in addition to its inhibitory potency against luciferase activity (IC50﹤10 nM), also activates AMPK signaling by increasing cellular ADP/ATP ratio via mitochondria respiration upcoupling, effectively activating AMPK & PGC-1α in muscle, but not liver, cell types both in cultures (5-20 µM in rat L6 myotubes) in vitro and in db/db mice (15 mg/kg/day via p.o.) in vivo. Reported to improve glucose and insulin tolerance of db/db mice without any apparent effects on body weight or food intake.

Legal Information

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

Other Notes

Zhang, L.N., et al. 2013. Diabetes.62, 1297.

Packaging

Packaged under inert gas

Reconstitution

Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 6 months at -20°C.

Warning

Toxicity: Standard Handling (A)

assay≥99% (HPLC)
colorpink-white
formpowder
InChI keyLQUNNCQSFFKSSK-UHFFFAOYSA-N
InChI1S/C17H18N2/c1-17(2,3)13-10-8-12(9-11-13)16-18-14-6-4-5-7-15(14)19-16/h4-11H,1-3H3,(H,18,19)
manufacturer/tradenameCalbiochem®
Quality Level100
solubilityDMSO: 50 mg/mL
storage conditionprotect from light, OK to freeze
storage temp.2-8°C
Cas Number49671-76-3
This product has met the following criteria to qualify for the following awards:



PROCEED TO CHECKOUT

HAVE AN ACCOUNT? LOGIN


GUEST CHECKOUT

Proceed as a guest. You will have the option to register to access exclusive pricing and stock availability features after checkout.